Brazil Vaccines Market Overview, 2028

The Brazil Vaccines market is anticipated to grow at more than 7% CAGR from 2023–2028.

Brazil has a comprehensive National Immunisation Programme that provides vaccines free of charge to the entire population. The PNI is a cornerstone of public health in Brazil and has contributed significantly to the prevention of vaccine-preventable diseases. Brazil has legislation that mandates certain vaccines for specific age groups. For example, vaccines against diseases like measles, mumps, rubella, diphtheria, tetanus, and pertussis (DPT) are required for children entering school. These mandates help ensure high vaccine coverage rates. During the annual Carnaval festivities, Brazil often conducts vaccination campaigns. These campaigns provide an opportunity for individuals to receive vaccines while participating in cultural celebrations. Brazil uses various forms of media and public health messaging to inform the population about the importance of vaccines. These campaigns target a wide audience and aim to dispel myths and misinformation about vaccination. Brazil is home to several vaccine production facilities, including the Butantan Institute and Fiocruz, which produce a significant portion of the vaccines used in the country. These institutions have a long history of vaccine production. Brazil conducts mass vaccination campaigns, often during specific periods of the year or in response to disease outbreaks. These campaigns target various age groups and prioritise specific vaccines. For example, there are annual campaigns for the influenza (flu) vaccine. Brazil often uses the festive atmosphere of the annual Carnaval celebrations to conduct vaccination campaigns. Mobile vaccination units and clinics may be set up near Carnaval venues to provide vaccines to participants and attendees. According to the research report, "Brazil Vaccines Market Outlook, 2028," published by Bonafide Research, the Brazil Vaccines market is anticipated to grow at more than 7% CAGR from 2023–2028. Brazil's experience with emerging infectious diseases like Zika and the response to the COVID-19 pandemic have underscored the need for vaccines. These events have prompted investments in vaccine research and development. Brazil has a growing pharmaceutical industry, including vaccine production. Local and international vaccine manufacturers operate in the country, contributing to a diverse vaccine market. Public health campaigns and educational initiatives raise awareness about vaccines and address vaccine hesitancy, ultimately increasing vaccine acceptance. The Brazilian government operates the National Immunisation Programme (PNI), a comprehensive programme that offers free vaccines to the entire population. The PNI provides a schedule of recommended vaccines, ensures vaccine procurement, and coordinates nationwide vaccination campaigns. Before vaccines can be distributed and administered in Brazil, they must receive regulatory approval from the National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, or ANVISA). ANVISA assesses the safety, quality, and efficacy of vaccines to ensure they meet international standards. The government mandates specific vaccines for certain age groups and occupations to maintain high vaccine coverage rates. For example, vaccines like DPT (diphtheria, tetanus, and pertussis) are required for children entering school. The Brazilian Ministry of Health is responsible for vaccine procurement and distribution. The government negotiates with vaccine manufacturers to secure affordable prices for vaccines, making them accessible to the population. The government organises regular immunisation campaigns, such as the annual influenza vaccination campaign. These campaigns raise awareness and encourage vaccine uptake among the population. Based on the technology types, they include conjugated vaccines, inactivated and subunit vaccines, live-attenuated vaccines, recombinant vaccines, and toxoid vaccines. In Brazil, the market for inactivated and subunit vaccines is growing. Inactivated and subunit vaccines are known for their safety and efficacy profiles. They have been extensively studied and have a well-established track record of protecting against specific diseases. Brazil's National Immunisation Programme (PNI) includes several inactivated and subunit vaccines as part of its recommended vaccination schedule. This inclusion ensures that these vaccines are widely available and administered to the population. Brazil actively participates in global health initiatives that promote the use of inactivated and subunit vaccines. These collaborations facilitate access to vaccines and promote their adoption. Over time, the indications for certain inactivated and subunit vaccines may expand to include new age groups or at-risk populations, contributing to increased market demand.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Based on the route of administration, they are segmented into intramuscular and subcutaneous administration, oral administration, and others. In the country where the Oral Administration is growing, Brazil has a history of using oral vaccines for diseases like polio. These experiences have laid the foundation for the acceptance and administration of oral vaccines in the country. Brazil has implemented national vaccination campaigns that target a wide range of infectious diseases. Some of these campaigns involve the administration of oral vaccines to reach large populations efficiently. The use of oral vaccines is often favored for mass immunisation programmes, where reaching many people quickly is essential. These programmes may target specific diseases or populations, such as children. Brazil has implemented various public health initiatives to increase vaccine coverage. These initiatives may include the use of oral vaccines to protect against diseases like rotavirus. Oral vaccines are generally well-accepted by the public, particularly among children and individuals with needle phobias. The convenience of oral administration can lead to higher vaccination rates and better coverage. In terms of disease types, they include the rotavirus, pneumococcal diseases, cancer, influenza, diphtheria, pertussis, and tetanus, the human papilloma virus (HPV), hepatitis, shingles, meningococcal diseases, varicella, mumps, and others. Brazil has a well-established routine immunisation Programme that includes the administration of the DTP vaccine. This Programme ensures that infants and children receive the DTP vaccine as part of their scheduled vaccinations. Diphtheria, pertussis (whooping cough), and tetanus are serious diseases that can lead to severe illness and even death, particularly in young children. Brazil has experienced outbreaks of these diseases in the past, emphasising the importance of vaccination. The Brazilian government has demonstrated a commitment to vaccination as a public health priority. This commitment includes the inclusion of the DTP vaccine in the National Immunisation Programme (PNI), which aims to provide access to vaccines for all citizens. Brazil has a well-developed healthcare infrastructure with trained healthcare professionals who administer vaccines, including the DTP vaccine, in clinics and healthcare centers throughout the country According to the report, types are segmented into multivalent vaccines and monovalent vaccines. In the USA, multivalent vaccines are the leading market. Multivalent vaccines combine protection against multiple diseases into a single vaccine, reducing the number of shots needed. This simplification is particularly advantageous for infants and children who require numerous vaccinations in their early years, making it easier for parents and healthcare providers to adhere to the recommended vaccination schedule. Fewer injections increase the likelihood of individuals and parents complying with the recommended vaccination schedule. This results in higher vaccination rates and better public health outcomes. Combination vaccines are more efficient in terms of healthcare resources and logistics. They reduce the number of healthcare visits, the need for multiple syringes, and the storage space required for vaccines.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

End users are segmented into the adult and paediatric markets; in Brazil, the paediatric market is leading as the end user in the country. Brazilian legislation mandates specific vaccines for children entering school. These mandates make it obligatory for parents to ensure that their children receive recommended vaccines before enrolling in educational institutions, driving high vaccine coverage rates among children. Many vaccines, such as those against measles, mumps, rubella (MMR), diphtheria, tetanus, and pertussis (DPT), are administered during infancy and early childhood. These vaccines are crucial for protecting children from severe diseases. Brazil's healthcare infrastructure ensures that paediatric vaccines are readily available at health posts, clinics, and healthcare facilities across the country. Brazil's public health policies receive substantial parental support, with many parents actively seeking to vaccinate their children according to the recommended schedule. According to the report, the distribution channels include hospital pharmacy, retail pharmacy, institutional sales, and others. In Brazil, the hospital pharmacy is the leading distribution channel. Brazil's healthcare system is heavily reliant on hospitals. They frequently have the facilities, tools, and trained staff needed to handle and deliver immunisations properly. In particular, for some vaccinations that require careful monitoring, hospitals have healthcare experts, including nurses and physicians, who may administer vaccines and offer the required medical supervision. Some vaccines, particularly those required for travel or specific medical conditions, are available at hospital pharmacies, catering to patients' specialised needs. The hospital pharmacy has a supply of vaccinations on hand to make sure that patients who need immunisation as part of their treatment get it right away. Some hospitals in Brazil offer travel clinics where individuals can receive the vaccines required for international travel. These clinics provide convenient access to travel-related vaccines. Brazil's large and diverse population offers a substantial market for vaccines. Meeting the vaccination needs of various demographic groups, including children, adults, and the elderly, presents a significant opportunity for vaccine manufacturers and providers. The Brazilian government's commitment to vaccination is a major opportunity. The National Immunisation Programme (PNI) ensures the widespread distribution of vaccines, and government initiatives promote vaccination campaigns and coverage. Vaccination is a proven tool for disease prevention, and Brazil has made progress in controlling and eradicating vaccine-preventable diseases. Continued efforts to expand vaccination coverage can lead to further disease control and a reduction in healthcare costs. Brazil's pharmaceutical industry, including vaccine production, has been growing. Domestic and international manufacturers have invested in vaccine production facilities, creating opportunities for innovation and expansion. Brazil faces healthcare inequalities, with disparities in access to healthcare services and vaccines between urban and rural areas and among different socioeconomic groups. Ensuring equitable vaccine distribution is a challenge. Vaccine hesitancy and misinformation exist in Brazil, leading to pockets of low vaccine coverage and outbreaks of vaccine-preventable diseases. Addressing vaccine hesitancy through public health campaigns and education is essential.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Considered in this report: • Geography: Brazil, • Historic year: 2017 • Base year: 2022 • Estimated year: 2023 • Forecast year: 2028 Aspects covered in this report: • Brazil Vaccines market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Technology • Conjugate vaccines • Inactivated & Subunit vaccines • Live Attenuated vaccines • Recombinant vaccines • Toxoid vaccines • Viral vector vaccines • Others By Route of Administration • Intramuscular and Subcutaneous Administration • Oral Administration • Others By Disease • Rotavirus • Pneumococcal diseases • Cancer • Influenza • Diphtheria, Pertussis, and Tetanus (DTP) • Human Papilloma Virus (HPV) • Hepatitis • Shingles • Meningococcal diseases • Varicella (Chicken Pox) • Mumps • Others By Type • Multivalent vaccines • Monovalent vaccines By End-User Type • Paediatrics • Adults By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy • Others The approach of the report: This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources. Intended audience: This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

Table of Contents

  • Table of Contents
  • 1. Executive Summary
  • 2. Market Structure
  • 2.1. Market Considerate
  • 2.2. Assumptions
  • 2.3. Limitations
  • 2.4. Abbreviations
  • 2.5. Sources
  • 2.6. Definitions
  • 2.7. Geography
  • 3. Research Methodology
  • 3.1. Secondary Research
  • 3.2. Primary Data Collection
  • 3.3. Market Formation & Validation
  • 3.4. Report Writing, Quality Check & Delivery
  • 4. Brazil Macro Economic Indicators
  • 5. Market Dynamics
  • 5.1. Key Findings
  • 5.2. Key Developments - 2021
  • 5.3. Market Drivers & Opportunities
  • 5.4. Market Restraints & Challenges
  • 5.5. Market Trends
  • 5.6. Covid-19 Effect
  • 5.7. Supply chain Analysis
  • 5.8. Policy & Regulatory Framework
  • 5.9. Industry Experts Views
  • 6. Brazil Vaccines Market Overview
  • 6.1. Market Size By Value
  • 6.2. Market Size and Forecast By Technology
  • 6.3. Market Size and Forecast By End-User
  • 6.4. Market Size and Forecast By Distribution Channel
  • 6.5. Market Size and Forecast By Type
  • 6.6. Market Size and Forecast By Route of Administration
  • 6.7. Market Size and Forecast By Disease
  • 7. Brazil Vaccines Market Segmentations
  • 7.1. Brazil Vaccines Market, By Technology
  • 7.1.1. Brazil Vaccines Market Size, By Conjugate Vaccines, 2017-2028
  • 7.1.2. Brazil Vaccines Market Size, By Inactivated & Subunit Vaccines, 2017-2028
  • 7.1.3. Brazil Vaccines Market Size, By Live Attenuated Vaccines, 2017-2028
  • 7.1.4. Brazil Vaccines Market Size, By Recombinant Vaccines, 2017-2028
  • 7.1.5. Brazil Vaccines Market Size, By Toxoid Vaccines, 2017-2028
  • 7.2. Brazil Vaccines Market, By End-User
  • 7.2.1. Brazil Vaccines Market Size, By Pediatric Vaccines, 2017-2028
  • 7.2.2. Brazil Vaccines Market Size, By Adult Vaccines, 2017-2028
  • 7.3. Brazil Vaccines Market, By Distribution Channel
  • 7.3.1. Brazil Vaccines Market Size, By Hospital Pharmacy, 2017-2028
  • 7.3.2. Brazil Vaccines Market Size, By Retail Pharmacy, 2017-2028
  • 7.3.3. Brazil Vaccines Market Size, By Institutional Sales, 2017-2028
  • 7.3.4. Brazil Vaccines Market Size, By Others, 2017-2028
  • 7.4. Brazil Vaccines Market, By Type
  • 7.4.1. Brazil Vaccines Market Size, By Multivalent vaccines, 2017-2028
  • 7.4.2. Brazil Vaccines Market Size, By Monovalent vaccines, 2017-2028
  • 7.5. Brazil Vaccines Market, By Route of Administration
  • 7.5.1. Brazil Vaccines Market Size, By Intramuscular and Subcutaneous Administration, 2017-2028
  • 7.5.2. Brazil Vaccines Market Size, By Oral Administration, 2017-2028
  • 7.5.3. Brazil Vaccines Market Size, By Others, 2017-2028
  • 7.6. Brazil Vaccines Market, By Route of Disease
  • 7.6.1. Brazil Vaccines Market Size, By Rotavirus, 2017-2028
  • 7.6.2. Brazil Vaccines Market Size, By Pneumococcal diseases, 2017-2028
  • 7.6.3. Brazil Vaccines Market Size, By Cancer, 2017-2028
  • 7.6.4. Brazil Vaccines Market Size, By Influenza, 2017-2028
  • 7.6.5. Brazil Vaccines Market Size, By Rotavirus, 2017-2028
  • 7.6.6. Brazil Vaccines Market Size, By Diphtheria, Pertussis, and Tetanus (DTP), 2017-2028
  • 7.6.7. Brazil Vaccines Market Size, By Human Papilloma Virus (HPV), 2017-2028
  • 7.6.8. Brazil Vaccines Market Size, By Hepatitis, 2017-2028
  • 7.6.9. Brazil Vaccines Market Size, By Shingles, 2017-2028
  • 7.6.10. Brazil Vaccines Market Size, By Meningococcal diseases, 2017-2028
  • 7.6.11. Brazil Vaccines Market Size, By Varicella (Chicken Pox), 2017-2028
  • 7.6.12. Brazil Vaccines Market Size, By Mumps, 2017-2028
  • 7.6.13. Brazil Vaccines Market Size, By Others, 2017-2028
  • 8. Brazil Vaccines Market Opportunity Assessment
  • 8.1. By Technology, 2023 to 2028
  • 8.2. By End-User, 2023 to 2028
  • 8.3. By Distribution Channel, 2023 to 2028
  • 8.4. By Type, 2023 to 2028
  • 8.5. By Route of Administration, 2023 to 2028
  • 8.6. By Route of Administration, 2023 to 2028
  • 9. Competitive Landscape
  • 9.1. Porter's Five Forces
  • 9.2. Company Profile
  • 9.2.1. Company 1
  • 9.2.2. Company 2
  • 9.2.3. Company 3
  • 9.2.4. Company 4
  • 9.2.5. Company 5
  • 9.2.6. Company 6
  • 9.2.7. Company 7
  • 9.2.8. Company 8
  • 10. Strategic Recommendations
  • 11. Disclaimer

List of Table
Table 1 : Influencing Factors for Global Vaccines Market, 2022
Table 2: Brazil Vaccines Market Size and Forecast By Technology (2017, 2022 & 2028F)
Table 3: Brazil Vaccines Market Size and Forecast By End-User (2017, 2022 & 2028F)
Table 4: Brazil Vaccines Market Size and Forecast By Distribution Channel (2017, 2022 & 2028F)
Table 5: Brazil Vaccines Market Size and Forecast By Type (2017, 2022 & 2028F)
Table 6: Brazil Vaccines Market Size and Forecast By Route of Administration (2017, 2022 & 2028F)
Table 7: Brazil Vaccines Market Size and Forecast By Disease (2017, 2022 & 2028F)
Table 8: Brazil Vaccines Market Size of Conjugate Vaccines (2017 to 2028) in USD Million
Table 9: Brazil Vaccines Market Size of Inactivated & Subunit Vaccines (2017 to 2028) in USD Million
Table 10: Brazil Vaccines Market Size of Live Attenuated Vaccines (2017 to 2028) in USD Million
Table 11: Brazil Vaccines Market Size of Recombinant Vaccines (2017 to 2028) in USD Million
Table 12: Brazil Vaccines Market Size of Toxoid Vaccines (2017 to 2028) in USD Million
Table 13: Brazil Vaccines Market Size of Pediatric Vaccines (2017 to 2028) in USD Million
Table 14: Brazil Vaccines Market Size of Adult Vaccines (2017 to 2028) in USD Million
Table 15: Brazil Vaccines Market Size of Hospital Pharmacy (2017 to 2028) in USD Million
Table 16: Brazil Vaccines Market Size of Retail Pharmacy (2017 to 2028) in USD Million
Table 17: Brazil Vaccines Market Size of Institutional Sales (2017 to 2028) in USD Million
Table 18: Brazil Vaccines Market Size of Others (2017 to 2028) in USD Million
Table 19: Brazil Vaccines Market Size of Multivalent vaccines (2017 to 2028) in USD Million
Table 20: Brazil Vaccines Market Size of Monovalent vaccines (2017 to 2028) in USD Million
Table 21: Brazil Vaccines Market Size of Intramuscular and Subcutaneous Administration (2017 to 2028) in USD Million
Table 22: Brazil Vaccines Market Size of Oral Administration (2017 to 2028) in USD Million
Table 23: Brazil Vaccines Market Size of Others (2017 to 2028) in USD Million
Table 24: Brazil Vaccines Market Size of Rotavirus (2017 to 2028) in USD Million
Table 25: Brazil Vaccines Market Size of Pneumococcal diseases (2017 to 2028) in USD Million
Table 26: Brazil Vaccines Market Size of Cancer (2017 to 2028) in USD Million
Table 27: Brazil Vaccines Market Size of Influenza (2017 to 2028) in USD Million
Table 28: Brazil Vaccines Market Size of Rotavirus (2017 to 2028) in USD Million
Table 29: Brazil Vaccines Market Size of Diphtheria, Pertussis, and Tetanus (DTP) (2017 to 2028) in USD Million
Table 30: Brazil Vaccines Market Size of Human Papilloma Virus (HPV) (2017 to 2028) in USD Million
Table 31: Brazil Vaccines Market Size of Hepatitis (2017 to 2028) in USD Million
Table 32: Brazil Vaccines Market Size of Shingles (2017 to 2028) in USD Million
Table 33: Brazil Vaccines Market Size of Meningococcal diseases (2017 to 2028) in USD Million
Table 34: Brazil Vaccines Market Size of Varicella (Chicken Pox) (2017 to 2028) in USD Million
Table 35: Brazil Vaccines Market Size of Mumps (2017 to 2028) in USD Million
Table 36: Brazil Vaccines Market Size of Others (2017 to 2028) in USD Million

List of Figures
Figure 1: Brazil Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Million)
Figure 2: Market Attractiveness Index, By Technology
Figure 3: Market Attractiveness Index, By End-User
Figure 4: Market Attractiveness Index, By Distribution Channel
Figure 5: Market Attractiveness Index, By Type
Figure 6: Market Attractiveness Index, By Route of Administration
Figure 7: Market Attractiveness Index, By Route of Administration
Figure 8: Porter's Five Forces of Brazil Vaccines Market
Logo

Brazil Vaccines Market Overview, 2028

Contact usWe are friendly and approachable, give us a call.